Ken Shulman

Ken Shulman is a seasoned professional in the pharmaceutical industry with extensive experience in clinical development and medical affairs. Currently serving as Senior Director of Clinical Development at Teva Pharmaceuticals since January 2020, Shulman previously held leadership roles at Curelator Inc. as Vice President of Medical Affairs, Avanir Pharmaceuticals as Senior Director of Migraine Medical Affairs, and Genzyme as Medical Director for US Medical Affairs in Multiple Sclerosis. Prior to these positions, Shulman was the Director of Neurosciences Clinical Development and Senior Medical Science Liaison at GlaxoSmithKline, alongside a role as Clinical Neurologist at The Neurology Group of Bucks/Montgomery County. Shulman earned a Doctor of Osteopathic Medicine from Kansas City University and a Bachelor of Arts in Biology from Boston University, also holding an earlier degree in Biology from Muhlenberg College.